Patents by Inventor Thomas Hunziker
Thomas Hunziker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240090536Abstract: The embodiments disclosed herein are directed to clear liquid formulations comprising: a) at least one carotenoid, and b) at least one modified food starch, and c) at least one saccharide, and d) water The present invention is further directed to a process for the manufacture of such liquid formulations, as well as to beverages containing the same. These beverages are also clear and color stable.Type: ApplicationFiled: November 7, 2023Publication date: March 21, 2024Inventors: David SCHAFFNER, Gabriela BADOLATO BÖNISCH, André HUNZIKER, Thomas ZWICK
-
Patent number: 9173906Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.Type: GrantFiled: February 10, 2014Date of Patent: November 3, 2015Assignee: Smith & Nephew, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Chevallay, Christopher Rinsch
-
Publication number: 20140377229Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.Type: ApplicationFiled: February 10, 2014Publication date: December 25, 2014Applicant: SMITH & NEPHEW, INC.Inventors: Eric ROLLAND, Thomas HUNZIKER, Beatrice CHEVALLAY, Christopher RINSCH
-
Patent number: 8679475Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: GrantFiled: October 24, 2012Date of Patent: March 25, 2014Assignee: Smith & Nephew, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Chevallay, Christopher Rinsch
-
Patent number: 8323638Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6 IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.Type: GrantFiled: February 8, 2012Date of Patent: December 4, 2012Assignee: DFB Technology Holdings, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20120134962Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.Type: ApplicationFiled: February 8, 2012Publication date: May 31, 2012Applicant: DFB TECHNOLOGY HOLDINGS, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 8137965Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: GrantFiled: December 14, 2010Date of Patent: March 20, 2012Assignee: DFB Technology Holdings, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20120064049Abstract: The present invention relates to the use of stem cells from hair root sheaths and/or keratinocyte precursor cells for the regeneration of aged but otherwise healthy and non-injured skin for the cosmetic purposes and for the prevention of skin diseases. In addition, the invention is directed to a cosmetic method for the regeneration of aged skin.Type: ApplicationFiled: May 28, 2010Publication date: March 15, 2012Applicant: SKINREPHAIR LTD.Inventor: Thomas Hunziker
-
Publication number: 20110083987Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: ApplicationFiled: December 14, 2010Publication date: April 14, 2011Applicant: DFB TECHNOLOGY HOLDINGS, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7879605Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-ID, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.Type: GrantFiled: September 18, 2009Date of Patent: February 1, 2011Assignee: DFB Technology Holdings, LLCInventors: Eric Holland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20100310526Abstract: The present invention proposes a cosmetic method for increasing the pigmentation of skin with the steps application of melanocyte precursor cells from root sheaths collected from a first area of skin of a donor to a second area of skin of a recipient. Furthermore, the use of melanocyte precursor cells for increasing the pigmentation of skin as well as a method for producing a suspension having precursor cells from the root sheath is proposed.Type: ApplicationFiled: September 15, 2008Publication date: December 9, 2010Applicant: EURODERM GMBHInventor: Thomas Hunziker
-
Patent number: 7700351Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: GrantFiled: October 21, 2008Date of Patent: April 20, 2010Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20100068281Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.Type: ApplicationFiled: September 18, 2009Publication date: March 18, 2010Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20090257986Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.Type: ApplicationFiled: January 14, 2009Publication date: October 15, 2009Applicant: DFB Pharmaceuticals, Inc.Inventors: Thomas Hunziker, Alain Limat
-
Publication number: 20090232791Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: ApplicationFiled: October 21, 2008Publication date: September 17, 2009Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7449333Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: September 5, 2003Date of Patent: November 11, 2008Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7378519Abstract: Processes for isolation and purification of enantiomerically enriched compositions comprising tramadol and topiramate, and also for the subsequent isolation of 1S,2S-tramadol hydrochloride, are disclosed herein.Type: GrantFiled: May 16, 2003Date of Patent: May 27, 2008Assignee: Cilag GmbH InternationalInventors: Rainer Naeff, Sonja Spycher-Huber, Thomas Hunziker, Guenter Laufer
-
Publication number: 20070036732Abstract: Bi- or multi-phasic tablets comprising an effective amount of a moisture sensitive active ingredient, which in particular is topiramate, wherein at least one of the phases comprises hygroscopic gum material, which preferably is xanthan gum, and wherein none of the phases contains both moisture sensitive active ingredient and hygroscopic gum material.Type: ApplicationFiled: December 12, 2003Publication date: February 15, 2007Inventors: Reza Eivaskhani, Thomas Hunziker, Rene Spycher
-
Publication number: 20060292126Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.Type: ApplicationFiled: October 31, 2005Publication date: December 28, 2006Applicant: DFB Pharmaceuticals, Inc.Inventors: Thomas Hunziker, Alain Limat
-
Patent number: 7144729Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: December 19, 2002Date of Patent: December 5, 2006Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch